肝硬化门静脉高压的进展及挑战：以Baveno Ⅶ共识为新起点

张晓丰; 陈金军

doi:10.3969/j.issn.1001-5256.2022.06.001

肝硬化门静脉高压的进展及挑战：以Baveno Ⅶ共识为新起点

DOI: 10.3969/j.issn.1001-5256.2022.06.001

张晓丰^{1, 2},
陈金军^{1, 2, 3, , ,}

1.
南方医科大学南方医院肝病中心，广州 510515
2.
南方医科大学南方医院增城分院肝病科，广州 511300
3.
广东省肝脏疾病研究所，广州 510515

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：张晓丰负责查找文献，撰写文稿；陈金军负责确定写作思路，指导文章撰写及最后定稿。

详细信息

通信作者:
陈金军，chjj@smu.edu.cn

计量
- 文章访问数: 1078
- HTML全文浏览量: 274
- PDF下载量: 292
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-06
- 录用日期: 2022-06-06
- 出版日期: 2022-06-20

Advances and challenges in cirrhotic portal hypertension: A new start from the Baveno Ⅶ consensus

Xiaofeng ZHANG^{1, 2},
Jinjun CHEN^{1, 2, 3
, ,
,}

1.
Hepatology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2.
Department of Hepatology, Zengcheng Branch of Nanfang Hospital, Southern Medical University, Guangzhou 511300, China
3.
Hepatology Institute of Guangdong Province, Guangzhou 510515, China

More Information

Corresponding author: CHEN Jinjun, chjj@smu.edu.cn (ORCID: 0000-0003-4275-9149)

摘要

摘要: Baveno协作组发布门静脉高压的新共识(Baveno Ⅶ共识)，总结了门静脉高压的诊断标准、无创筛查和诊断、包括病因治疗及非病因治疗的一级预防、包括内镜和血管介入下诊治的二级预防、肝硬化失代偿相关新观念，以及肝脏血管病等方向的主要进展和研究日程。Baveno Ⅶ共识对我国门静脉高压相关领域临床实践和研究具有重要借鉴价值。本文从临床实践角度简述我国肝硬化门静脉高压的主要进展和挑战。
- 肝硬化 /
- 门静脉高压 /
- Baveno Ⅶ共识
Abstract: The new consensus on portal hypertension issued by Baveno Cooperative Group, i.e., the Baveno Ⅶ consensus, summarizes the diagnostic criteria for portal hypertension, noninvasive screening and diagnosis, primary prevention including etiological treatment and non-etiological treatment, secondary prevention including endoscopy and vascular intervention for diagnosis and treatment, new concepts associated with decompensated liver cirrhosis, and major advances and research agenda for the research directions including liver vascular diseases. Baveno Ⅶ consensus has an important reference value for clinical practice and research in the related fields of portal hypertension in China. As a part of the special issue, this article briefly describes the advances and challenges in portal hypertension in China from the perspective of clinical practice.
- Liver Cirrhosis /
- Portal Hypertension /
- Baveno Ⅶ Consensus

HTML全文

参考文献(20)

[1]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[2]	ZHANG XF, HE QJ, CHEN JJ. An excerpt of Report of the Baveno Ⅶ Consensus Workshop: Personalized care in portal hypertension[J]. J Clin Hepatol, 2022, 38(6): 1258-1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010. 张晓丰, 何钦俊, 陈金军. 《Baveno Ⅶ门静脉高压共识更新: 门静脉高压的个体化管理》摘译[J]. 临床肝胆病杂志, 2022, 38(6) 1258-1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010.
[3]	FERRUSQUÍA-ACOSTA J, BASSEGODA O, TURCO L, et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis[J]. J Hepatol, 2021, 74(4): 811-818. DOI: 10.1016/j.jhep.2020.10.003.
[4]	ZHANG W, PENG C, ZHANG S, et al. EUS-guided portal pressure gradient measurement in patients with acute or subacute portal hypertension[J]. Gastrointest Endosc, 2021, 93(3): 565-572. DOI: 10.1016/j.gie.2020.06.065.
[5]	ZHOU YJ, GAO F, LIU WY, et al. Screening for compensated advanced chronic liver disease using refined Baveno Ⅵ elastography cutoffs in Asian patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2021, 54(4): 470-480. DOI: 10.1111/apt.16487.
[6]	JI Y, LI J, HE Q, et al. Baveno Ⅵ elastography criteria for ruling in cACLD works well in patients with MAFLD[J]. J Hepatol, 2021, 75(5): 1243-1245. DOI: 10.1016/j.jhep.2021.06.003.
[7]	WANG H, WEN B, CHANG X, et al. Baveno Ⅵ criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis[J]. J Hepatol, 2021, 74(3): 584-592. DOI: 10.1016/j.jhep.2020.09.034.
[8]	YAN Y, LI Y, FAN C, et al. A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients[J]. Hepatol Int, 2022, 16(2): 423-432. DOI: 10.1007/s12072-021-10292-6.
[9]	LIU Y, NING Z, ÖRMECI N, et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2020, 18(13): 2998-3007. e5. DOI: 10.1016/j.cgh.2020.03.034.
[10]	QI X, AN W, LIU F, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology, 2019, 290(2): 370-377. DOI: 10.1148/radiol.2018180425.
[11]	SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
[12]	LV Y, ZUO L, ZHU X, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study[J]. Gut, 2019, 68(7): 1297-1310. DOI: 10.1136/gutjnl-2018-317057.
[13]	LUO X, XIANG T, WU J, et al. Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial[J]. Hepatology, 2021, 74(4): 2074-2084. DOI: 10.1002/hep.31718.
[14]	LV Y, CHEN H, LUO B, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial[J]. Hepatology, 2022. DOI: 10.1002/hep.32453.[Online ahead of print]
[15]	ZHANG Y, XU BY, WANG XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2564-2572. e1. DOI: 10.1016/j.cgh.2020.02.037.
[16]	LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: a prospective observational study[J]. Am J Gastroenterol, 2021, 116(7): 1447-1464. DOI: 10.14309/ajg.0000000000001194.
[17]	LV Y, HE C, WANG Z, et al. Association of nonmalignant portal vein thrombosis and outcomes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis[J]. Radiology, 2017, 285(3): 999-1010. DOI: 10.1148/radiol.2017162266.
[18]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Dig Dis, 2021, 22(4): 176-186. DOI: 10.1111/1751-2980.12970.
[19]	HE ZY, WANG BQ, YOU H. Reversal of cirrhotic decompensation: re-compensation[J]. Chin J Hepatol, 2019, 27(12): 915-916. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.002. 何志颖, 王冰琼, 尤红. 肝硬化失代偿的逆转: 再代偿[J]. 中华肝脏病杂志, 2019, 27(12): 915-916. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.002.
[20]	ZHUGE YZ, WANG Y, ZHANG F, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease[J]. Liver Int, 2018, 38(10): 1867-1874. DOI: 10.1111/liv.13684.